Daily Respiratory Research Analysis
Analyzed 188 papers and selected 3 impactful papers.
Summary
Three impactful studies advance respiratory science and care: a Journal of Experimental Medicine study reveals nasal CD4+ tissue-resident memory T cells that cross-protect against heterosubtypic influenza; a double-blind phase 2 RCT in The Lancet Respiratory Medicine tests the oral BTK inhibitor rilzabrutinib for uncontrolled asthma (negative primary endpoint but meaningful symptom gains); and a multicenter Italian primary-care cohort quantifies RSV hospitalization risk with age-specific estimates to inform prevention strategies.
Research Themes
- Mucosal immunity and cross-protection in influenza
- Oral targeted therapy for uncontrolled asthma (BTK inhibition)
- Primary-care epidemiology and hospitalization risk of pediatric RSV
Selected Articles
1. Nasal CD4+ tissue-resident memory T cells provide cross-protective immunity to influenza.
Using mouse models and human nasal tissue, the authors show that antigen-specific nasal CD4+ TRM persist after influenza and confer heterosubtypic protection. These TRM are heterogeneous, Th17-enriched, and depend on the CXCR6–CXCL16 axis for residency, suggesting a tractable target to enhance upper-airway vaccine protection.
Impact: Defines a mechanistic basis for upper-respiratory cross-protection and identifies the CXCR6–CXCL16 axis as a residency pathway, informing mucosal vaccine design.
Clinical Implications: Supports development of intranasal vaccines or adjuvants that promote nasal CD4+ TRM (especially Th17) via CXCR6–CXCL16, potentially broadening heterosubtypic protection against influenza.
Key Findings
- Antigen-specific nasal CD4+ TRM persist after IAV infection and protect against heterosubtypic challenge.
- Nasal CD4+ TRM are heterogeneous and transcriptionally distinct from lung TRM by single-cell RNA-seq.
- CXCR6–CXCL16 axis promotes residency of CD4+ TRM in nasal tissue.
- Mouse and human nasal tissues harbor Th17-enriched CD4+ TRM that aid local viral clearance and limit damage.
Methodological Strengths
- Integration of mouse infection models with human nasal tissue analyses
- Single-cell RNA-seq to define TRM heterogeneity and residency pathways
Limitations
- Predominantly preclinical; translational efficacy of targeting CXCR6–CXCL16 remains to be tested in humans
- Protection demonstrated in experimental settings; durability and breadth across strains require confirmation
Future Directions: Test intranasal vaccine/adjuvant strategies that enhance nasal CD4+ TRM via CXCR6–CXCL16 in humans; longitudinal studies to define TRM durability and cross-strain protection.
CD4 tissue-resident memory T cells (TRM) are crucial adaptive immune components involved in preventing influenza A virus (IAV) infection. Despite their importance, their physiological role in the upper respiratory tract, the first site of contact with IAV, remains unclear. Here, we find that, after IAV infection, antigen-specific CD4 TRM persist in the nasal tissue (NT) compartment after infection and provide protection upon heterosubtypic challenge. Single-cell RNA-sequencing analysis reveals that NT CD4 TRM are heterogeneous and transcriptionally distinct as compared with their lung counterparts. Mechanistically, we demonstrate that the CXCR6-CXCL16 axis promotes CD4 TRM residency in the NT. Furthermore, we show that the NT of mice and humans contains a high frequency of Th17 CD4 TRM that aid in local viral clearance and in reducing tissue damage. Collectively, our results support a robust physiological role for NT CD4 TRM in local protection during heterosubtypic IAV infection.
2. Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study.
In a 12-week, double-blind phase 2 RCT (n=196 randomized), rilzabrutinib did not significantly reduce loss-of-asthma-control events versus placebo but produced early and sustained improvements in asthma control scores after background therapy withdrawal. Safety was acceptable, with diarrhea most common and no infection signal.
Impact: Provides high-quality randomized evidence on an oral BTK inhibitor for uncontrolled asthma, showing clinically meaningful symptom benefits despite a negative primary endpoint.
Clinical Implications: Rilzabrutinib could be considered for further development as an oral adjunct in uncontrolled asthma focused on symptom control; future trials should refine endpoints and patient selection to capture responders.
Key Findings
- Loss-of-asthma-control events: 38% with 800 mg vs 50% placebo; 19% with 1200 mg vs 29% placebo (not statistically significant).
- Asthma control improved from week 2 and was sustained to week 12 after background therapy withdrawal (LS mean difference −0.59 and −0.54 for 800 mg and 1200 mg, respectively).
- Safety profile acceptable: diarrhea most frequent; no increased infections observed.
Methodological Strengths
- Multinational, double-blind, placebo-controlled randomized design
- Pre-specified dosing cohorts and standardized withdrawal to stress test symptom control
Limitations
- Primary endpoint (LOAC reduction) not met; 12-week duration may be insufficient to detect exacerbation differences
- Responder subgroups and optimal endpoints require clarification
Future Directions: Phase 3 trials with longer follow-up, enriched populations (e.g., type 2–low or BTK-pathway signatures), and clinically meaningful composite endpoints (symptoms, exacerbations, lung function).
BACKGROUND: Uncontrolled symptomatic asthma is a substantial challenge for patients despite optimised treatment. Bruton's tyrosine kinase (BTK) plays a key part in immune cell signalling involved in airway inflammation, and its inhibition might improve asthma control. We aimed to explore the effects of BTK inhibition by oral rilzabrutinib on asthma control as well as safety in participants with moderate-to-severe asthma with uncontrolled symptoms. METHODS: This double-blind, placebo-controlled, phase 2 study, which was done at 48 centres across 13 countries, enrolled people aged 18-70 years with physician-diagnosed moderate-to-severe asthma for at least 12 months with uncontrolled symptoms on inhaled glucocorticoids plus a long-acting β
3. Clinical presentation and hospitalisation risk of RSV in primary care among children younger than 5 years in Italy in four seasons between 2019 and 2023: a multicentre prospective cohort study.
In a multicenter Italian primary-care cohort (n=1410 ARI; 566 RSV+), 4.4% of RSV-positive children were hospitalized, with the highest risk in infants <6 months (observed 16.2%; model-estimated 12.5% at birth). Illness commonly persisted beyond 2 weeks, and fever did not distinguish RSV from other pathogens, informing surveillance definitions and prevention targets.
Impact: Provides age-specific hospitalization risk estimates from primary care, directly informing HTAs and prioritization for RSV preventive strategies (maternal vaccine, nirsevimab).
Clinical Implications: Supports extending RSV prevention focus to the highest-risk early infancy while recognizing persistent risk beyond 24 months; fever-independent case definitions improve surveillance sensitivity.
Key Findings
- Among 566 RSV-positive children, 4.4% were hospitalized; median stay 5 days.
- Hospitalization risk highest in early infancy: observed 16.2% (<6 months); estimated 12.5% at birth (95% CI 3.4–33.1%).
- Illness duration averaged 15.2 days; 40.9% symptomatic at day 14; 15.4% at day 30.
- Fever did not differentiate RSV from other ARI pathogens (p=0.084).
Methodological Strengths
- Prospective, multicenter primary-care enrollment across multiple seasons
- RT-PCR confirmation with 14- and 30-day follow-up of RSV-positive cases
Limitations
- Conducted in Italy; generalizability to other health systems may vary
- Season 2020–2021 excluded; hospitalization events relatively few (4.4%), limiting subgroup precision
Future Directions: Expand to multinational primary-care networks, integrate vaccine/immunoprophylaxis status, and model cost-effectiveness using age-specific risks.
BACKGROUND: Respiratory syncytial virus (RSV) significantly contributes to pediatric morbidity globally. Severe cases are more common in infants and children with underlying health conditions, but even mild infections can result in long-term respiratory issues. While the RSV disease is well-documented in hospital settings, its clinical presentation and hospitalization risk in primary care, the initial point of healthcare access, remains unclear. METHODS: We conducted a multi-center prospective cohort study across multiple regions in Italy during four seasons (from 2019 to 2020 to 2023-2024), excluding 2020-2021. Children ≤5 years with acute respiratory infection (ARI), meeting the WHO case definition for community-based surveillance, were enrolled through primary care pediatricians. Nasopharyngeal swabs were collected and tested with RT-PCR. Clinical data were collected at baseline for all participants and at follow-up intervals of 14 and 30 days post-enrollment for RSV-positive children. FINDINGS: Among 1410 enrolled children with ARIs, RSV was laboratory-confirmed in 40.2% (n = 566). The mean duration of illness among RSV-positive children was 15.2 days (SD 8.8 days), with symptoms persisting in 40.9% of cases at day 14 and 15.4% at day 30. Hospitalization occurred in 4.4% (25/566) of RSV-positive cases, with a median hospital stay of 5 days (IQR: 4-7 days). Younger age was identified as the primary predictor of hospitalization (observed hospitalization rate of 16.2% in children under 6 months), with an estimated hospitalization risk of 12.5% at birth (95% CI: 3.4-33.1%). Fever did not differentiate RSV infection from other respiratory pathogens (p = 0.084). INTERPRETATION: Our study highlights the significant hospitalization risks associated with RSV infections among children presenting in primary care settings, offering detailed age-specific risk estimates crucial for accurate health technology assessments (HTAs) of preventive strategies. The findings strongly support exploring the expansion of RSV preventive interventions beyond the conventional age threshold of 24 months, considering the persisting risk in older children. Furthermore, we emphasize the importance of adopting a case definition without a mandatory fever criterion to enhance the sensitivity of RSV surveillance and thus improve the validity of disease-related estimates. FUNDING: RSV ComNet is a collaborative study funded by Sanofi and AstraZeneca. Study design and planning were undertaken in collaboration with Sanofi researchers. All data collection, analyses, interpretation, manuscript drafting, and the decision to submit for publication were performed independently by the authors. No datasets were shared with the funding parties.